We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NATL:NYSENCR Atleos Corporation Analysis

Data as of 2026-04-19 - not real-time

$45.69

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

NATL is trading at $45.69, comfortably above its 20‑day SMA of $43.90 and 50‑day SMA of $43.39, with price near the $46.29 resistance. The 14‑day RSI sits at 65, indicating momentum but approaching overbought territory, while MACD remains bullish (line $0.53 above signal $0.38). Volume has been tapering, yet the 30‑day volatility of ~19.8% and beta around 1.2 suggest moderate price swings. The DCF fair‑value estimate of $60.06 implies roughly a 10% upside, and the forward P/E of 8.1 is well below the industry average P/E of 36.7. The company’s trailing P/E of 21.35 also points to relative cheapness. Meanwhile, the Fear‑Greed Index at “Extreme Greed” (90.2) signals strong market appetite.
Fundamentals show modest 4% revenue growth on $4.35 B sales, but margins are thin (gross 24.4%, profit 3.7%) and leverage is extreme with a debt‑to‑equity of 739%, raising balance‑sheet risk. ROE of 51.8% is inflated by the low equity base, while cash on hand ($456 M) covers only a fraction of the $2.97 B debt. No dividend is paid, so dividend sustainability is nil. The most material catalyst is the announced $6.6 B acquisition by Brink’s, which could deliver a premium to current shareholders and accelerate cash‑flow synergies. However, deal execution and integration risk remain key uncertainties. Overall, the stock appears undervalued but carries elevated financial and execution risks.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Acquisition premium potential
  • Bullish technical setup
  • Undervalued relative to DCF

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward earnings expansion (EPS $5.66)
  • Significant upside to fair value
  • Synergy upside from Brink’s integration

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and balance‑sheet risk
  • Integration and execution uncertainty
  • Low dividend yield and reliance on growth catalysts

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin3.72%
P/E Ratio21.4
ROE51.84%
ROA6.04%
Debt/Equity739.30
P/B Ratio8.4
Op. Cash Flow$356.0M
Free Cash Flow$433.4M
Industry P/E36.7

Technical Analysis

TrendBullish
RSI65.1
Support$42.10
Resistance$46.29
MA 20$43.89
MA 50$43.39
MA 200$38.27
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21

Valuation

Fair Value$60.06
Target Price$50.27
Upside/Downside10.02%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.23
Volatility19.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.